Apr 252013
 

Life sciences companies in the U.S. raised roughly $404 million through ATMs in 2012, compared to $227 million in 2011, a 78 percent year-over-year increase.

In the fourth quarter of 2012, life sciences companies raised $128 million through ATMs, compared to $101 million in the third quarter, a 27 percent increase. This ATM activity included the following companies: StemCells Inc. (NASDAQ: STEM), Newark, Calif.; Sarepta Therapeutics Inc. (NASDAQ: SRPT), Cambridge, Mass.; Sunesis Pharmaceuticals Inc. (NASDAQ: SNSS), San Francisco, Calif.; Acadia Pharmaceuticals Inc. (NASDAQ: ACAD ), San Diego, Calif.

“The continued uptrend in ATM adoption and usage by life sciences companies is evident in these numbers,” says Todd Wyche, CEO of Brinson Patrick. “As we have predicted, an increasing number of life sciences companies continue to add ATMs to their financing toolkits to lower their cost of capital and avoid unnecessary dilution.”

ATM Proceeds - Life Sciences

 

 

 

Oct 252012
 

On October 1, we kicked off the third quarter with the publication of two news articles featuring Todd Wyche, CEO of Brinson Patrick.

The first, published by Growth Capital Investor, provides insights into the recent surge of interest in ATM offerings. The published article, which can be viewed online here, describes the growth in use of this tool in the past few years and some of the advantages, such as cost savings, that companies find appealing.

In addition, we recently worked with Robert Hoffman, chief financial officer for Arena, to provide recommendations for CFOs as we approach the end of the year. This article, published in the October 1 issue of Genetic Engineering & Biotechnology News, describes the specific steps that can be taken to be well-prepared from a financial perspective.

Apr 242012
 

 U.S. companies raised approximately $8 billion through ATMs in 2011, compared to $8.3 billion in 2010. The equity capital raised was through the activity of 209 ATM offerings of common stock across 20 industries, compared to the activity of 187 ATM offerings in 2010. $1.6 Billion Raised in fourth quarter last year.

Brinson Patrick Reports $8 Billion Raised by U.S. Companies Through At-The-Market (ATM) Offerings in 2011

Mar 222012
 

Today we are announcing the initiation of research coverage of Akorn, Inc.(NASDAQ: AKRX), a company that develops, manufactures and markets multisource and branded pharmaceuticals. The report, issued by our analyst Michael Higgins, is the first one of the firm’s new equity research department, which was established in January.

Brinson Patrick Securities Initiates Research Coverage of Akorn, Inc.